Cargando…
Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care c...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789336/ https://www.ncbi.nlm.nih.gov/pubmed/29295569 http://dx.doi.org/10.3390/brainsci8010005 |
_version_ | 1783296253798383616 |
---|---|
author | Haj, Amer Doenitz, Christian Schebesch, Karl-Michael Ehrensberger, Denise Hau, Peter Putnik, Kurt Riemenschneider, Markus J. Wendl, Christina Gerken, Michael Pukrop, Tobias Brawanski, Alexander Proescholdt, Martin A. |
author_facet | Haj, Amer Doenitz, Christian Schebesch, Karl-Michael Ehrensberger, Denise Hau, Peter Putnik, Kurt Riemenschneider, Markus J. Wendl, Christina Gerken, Michael Pukrop, Tobias Brawanski, Alexander Proescholdt, Martin A. |
author_sort | Haj, Amer |
collection | PubMed |
description | Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome. Patients and methods: The study included 149 patients treated surgically for newly diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score (KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation of the Regensburg NOC. The EOR and the PFS and OS were evaluated. Results: Prognostic factors for PFS and OS were age, preoperative KPS, O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status and EOR. Patients with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months; p = 0.042) and OS (18.4 vs. 14.5 months; p = 0.005) than patients with incomplete resection. The frequency of transient or permanent postoperative neurological deficits was not higher after complete resection in both subcohorts. The frequency of complete resection was significantly higher in subcohort B than in subcohort A (68.2% vs. 34.8%; p = 0.007). Accordingly, subcohort B showed significantly longer PFS (8.6 vs. 7.5 months; p = 0.010) and OS (18.7 vs. 12.4 months; p = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative KPS, and MGMT promoter status as independent prognostic factors for PFS and OS. Our data show a higher frequency of complete resection in patients with GBM after the establishment of a series of technical developments that resulted in significantly better PFS and OS without increasing surgery-related morbidity. |
format | Online Article Text |
id | pubmed-5789336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57893362018-02-02 Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center Haj, Amer Doenitz, Christian Schebesch, Karl-Michael Ehrensberger, Denise Hau, Peter Putnik, Kurt Riemenschneider, Markus J. Wendl, Christina Gerken, Michael Pukrop, Tobias Brawanski, Alexander Proescholdt, Martin A. Brain Sci Article Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome. Patients and methods: The study included 149 patients treated surgically for newly diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score (KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation of the Regensburg NOC. The EOR and the PFS and OS were evaluated. Results: Prognostic factors for PFS and OS were age, preoperative KPS, O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status and EOR. Patients with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months; p = 0.042) and OS (18.4 vs. 14.5 months; p = 0.005) than patients with incomplete resection. The frequency of transient or permanent postoperative neurological deficits was not higher after complete resection in both subcohorts. The frequency of complete resection was significantly higher in subcohort B than in subcohort A (68.2% vs. 34.8%; p = 0.007). Accordingly, subcohort B showed significantly longer PFS (8.6 vs. 7.5 months; p = 0.010) and OS (18.7 vs. 12.4 months; p = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative KPS, and MGMT promoter status as independent prognostic factors for PFS and OS. Our data show a higher frequency of complete resection in patients with GBM after the establishment of a series of technical developments that resulted in significantly better PFS and OS without increasing surgery-related morbidity. MDPI 2017-12-25 /pmc/articles/PMC5789336/ /pubmed/29295569 http://dx.doi.org/10.3390/brainsci8010005 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Haj, Amer Doenitz, Christian Schebesch, Karl-Michael Ehrensberger, Denise Hau, Peter Putnik, Kurt Riemenschneider, Markus J. Wendl, Christina Gerken, Michael Pukrop, Tobias Brawanski, Alexander Proescholdt, Martin A. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center |
title | Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center |
title_full | Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center |
title_fullStr | Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center |
title_full_unstemmed | Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center |
title_short | Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center |
title_sort | extent of resection in newly diagnosed glioblastoma: impact of a specialized neuro-oncology care center |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789336/ https://www.ncbi.nlm.nih.gov/pubmed/29295569 http://dx.doi.org/10.3390/brainsci8010005 |
work_keys_str_mv | AT hajamer extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT doenitzchristian extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT schebeschkarlmichael extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT ehrensbergerdenise extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT haupeter extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT putnikkurt extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT riemenschneidermarkusj extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT wendlchristina extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT gerkenmichael extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT pukroptobias extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT brawanskialexander extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter AT proescholdtmartina extentofresectioninnewlydiagnosedglioblastomaimpactofaspecializedneurooncologycarecenter |